The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Piper Sandler on December 12, 2024. The analyst firm set a price target for $163.00 expecting JAZZ to rise to within 12 months (a possible 31.74% upside). 45 analyst firms have reported ratings in the last year.

The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Piper Sandler, and Jazz Pharmaceuticals reiterated their overweight rating.

The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.

The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a reiterated with a price target of $163.00 to $163.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $123.73, which is out of the analyst’s predicted range.